Hyperhomocysteinaemia, methylenetetrahydrofolate reductase polymorphism and risk of coronary artery disease

Annals of Clinical Biochemistry

Volumn 43, Issue 3, 2006, Pages 200-206

  Kerkeni, Mohsen ^a,c   Addad, Faouzi ^b   Chauffert, Maryline ^c   Myara, Anne ^c   Gerhardt, Marie ^c   Chevenne, Didier ^c   Trivin, François ^c,e   Farhat, Mohamed Ben ^b   Miled, Abdelhedi ^d   Maaroufi, Khira ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^c SAINT JOSEPH HOSPITAL   (France)

^d FARHAT HACHED HOSPITAL   (Tunisia)

^e UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CHOLESTEROL; CREATININE; HOMOCYSTEINE; TRIACYLGLYCEROL;

ADULT; AGED; ARAB; ARTICLE; CARDIOVASCULAR RISK; CHEMOLUMINESCENCE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENZYME POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; TUNISIA;

ARABS; CASE-CONTROL STUDIES; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; CREATININE; FEMALE; GENOTYPE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS; TRIGLYCERIDES; TUNISIA;

EID: 33646348716     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/000456306776865232     Document Type: Article

References (31)

1. Ben Romdhane H, Bougatef S, Skiri H, et al. The first Tunisian cardiovascular diseases register: processus and results. Rev Epidemiol Sante Publique 2004; 52: 558-64
2. Winder AF. Homocysteine and cardiovascular disease. J Clin Pathol 1998; 51: 713-5
3. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998; 98: 2520-6
4. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001; 73: 613-21
5. Selhub J, Jacques PF, Rosenberg IH, et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 1999; 131: 331-9
6. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland homocysteine study. JAMA 1995; 274: 1526-33
7. Frosst P, Blom HJ, Milos R, et al. A candidate genetic for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3
8. Schwartz SM, Siscovick DS, Malinow MR, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96: 412-7
9. Brattstrom I, Wilcken DEL. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 2000; 72: 315-23
10. Ueland PM, Refsum H, Beresford SAA, Vollset SE. The controversy over homocysteine and cardiovascular risk. J Clin Nutr 2000; 72: 324-32
11. Werstruck GH, Lentz SR, Dayal S, et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 2001; 107: 1263-73
12. Loktionov A, Vorster H, O'Neill IK, et al. Apolipoprotein E and methylenetetrahydrofolate reductase genetic polymorphisms in relation to other risk factors for cardiovascular disease in UK Caucasians and Black South Africans. Atherosclerosis 1999; 145: 125-35
13. Qujeq D, Omran TS, Hosini L. Correlation between total homocysteine, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction. Clin Biochem 2001; 34: 97-101
14. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG, MTHFR studies collaboration group. MTHFR 677C-T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002; 288: 2023-31
15. Lewis SJ, Ebrahim S, Smith GD. Meta-analysis of MTHFR 677C-T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 2005; 331: 1053-9
16. Vallet-Colom I, Levy-Marchal C, Zarrouk D, et al. HLA-DQ B1 codon 57 and genetic susceptibility to type I (insulin-dependent) diabetes mellitus in French children. Diabetologia 1990; 33: 174-6
17. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-72
18. Hoogeveen EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus a population-based study. Arteroscler Thromb Vasc Biol 1998; 18: 133-8
19. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 527-31
20. Selhub J, D'Angelo A. Hyperhomocysteinemia and thrombosis: acquired conditions. Thromb Haemost 1997; 78: 527-31
21. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Inter Med 1999; 131: 363-75
22. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 2000; 160: 422-34
23. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015-22
24. Anderson JL, King GJ, Thomson MJ, et al. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarctus. J Am Coll Cardiol 1997; 30: 1206-11
25. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410-6
26. Van Bockxmeer FM, Mamotte CD, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 1997; 95: 21-3
27. Anderson JL, Muhlestein JB, Horne BD, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000; 102: 1227-32
28. Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 1998; 62: 1258-60
29. Murphy M, Vilella E, Ceruelo S, et al. The MTHFR C677T, APOE, and PON55 gene polymorphisms show relevant interactions with cardiovascular risk factors. Clin Chem 2002; 48: 372-5
30. Li H, Lewis A, Brodsky S, Rieger R, Iden C, Goligorsky MS. Homocysteine induces 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase in Vascular Endothelial Cells A Mechanism for Development of Atherosclerosis? Circulation 2002; 105: 1037-43
31. Woo CW, Siow YL, Pierce GN, et al. Hyperhomocysteinemia induces hepatic cholesterol biosynthesis and accumulation via activation of trascription factors. Am J Physiol Endocrinol Metab 2005; 5: 1002-10